

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA

PHONE: +91-124-4135000 FAX: +91-124-4106490

E-mail: secretarial@ranbaxy.com

December 15, 2014

TO : STOCK EXCHANGES

Dear Sirs,

Enclosed please find Press Release dated December 15, 2014 titled “**RANBAXY COMMENCES LAUNCH OF INDIA’S FIRST NCE, SYNRIAM™ IN AFRICAN COUNTRIES**” which is being issued by the Company today.

This is for your information please.

Thanking you,

Yours faithfully,
for RANBAXY LABORATORIES LTD.



(SUSHIL K . PATAWARI)
COMPANY SECRETARY

Encl.: As above.

RANBAXY LABORATORIES LIMITED

HEAD OFFICE: 12TH FLOOR, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI – 110019

REGISTERED OFFICE: A-41, INDUSTRIAL AREA PHASE VIII-A, SAHIBZADA AJIT SINGH NAGAR, MOHALI - 160071 (PUNJAB)

WEBSITE: <http://www.ranbaxy.com>

CIN : L24231PB1961PLC003747

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA
PHONE: +91-124-4135000 FAX: +91-124-4106490
E-mail: secretarial@ranbaxy.com

Press Release

RANBAXY COMMENCES LAUNCH OF INDIA'S FIRST NCE, SYNRIAM™ IN AFRICAN COUNTRIES

Gurgaon, India; December 15, 2014: Ranbaxy Laboratories Limited (Ranbaxy) today announced that it has received the regulatory approval to launch India's first NCE (New Chemical Entity), Synriam™ (arterolane maleate 150 mg + piperazine phosphate 750 mg drug) in seven African countries viz. Nigeria, Uganda, Senegal, Cameroon Guinea, Kenya and Ivory Coast. The product has since been launched in Uganda and will be made available in other countries towards end of January 2015.

The new drug conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Synriam™ provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 per cent.

On the occasion, Arun Sawhney, CEO and Managing Director, Ranbaxy said, "Most malaria cases and deaths occur in sub-Saharan Africa. It is the need of the hour to make available new therapy options to patients in the region. Synriam™ is among the best options available today as it is highly effective, affordable and a convenient therapy option, leading to better compliance. We are confident that the drug will help the government and healthcare system in Africa to fight the menace of malaria."

Double-blind, randomized, multi-center, Phase III clinical trial for the drug was conducted at multiple sites in Asia and Africa including India, Thailand, Bangladesh, Ivory Coast, Mozambique, Malawi, Senegal, Mali and Democratic Republic of Congo. This phase III clinical trial has demonstrated that Synriam™ (fixed dose combination of arterolane maleate and piperazine phosphate 150+750 mg) has comparable safety and efficacy profile to existing gold standard (fixed dose combination of artemether and lumefantrine 20 +120 mg) for treatment of acute uncomplicated *Plasmodium falciparum* malaria in patients aged 12 years and above.

Ranbaxy is also conducting Phase III clinical trials for the pediatric formulation of Synriam™ in pediatric patients of uncomplicated *Plasmodium falciparum* malaria.

Every year around 169 million people in Nigeria and around 32 million people in Uganda are at the risk of malaria. In Nigeria, Malaria contributes to an estimated 11% of maternal mortality. It is the number one public health problem in Guinea and according to national health statistics, the morbidity rate for malaria is 148/1000 population. The disease is endemic throughout Senegal, and the entire population (approximately 13.4 million) is at risk. Vulnerable groups comprise about 2.2 million children under five and 0.5 million pregnant women. About 70% of the Kenyan population is at risk for malaria. *Plasmodium falciparum* is the most predominant parasite species accounting for maximum malaria cases in these countries.



RANBAXY LABORATORIES LIMITED
HEAD OFFICE: 12TH FLOOR, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI - 110019
REGISTERED OFFICE: A-41, INDUSTRIAL AREA PHASE VIII-A, SAHIBZADA AJIT SINGH NAGAR, MOHALI - 160071 (PUNJAB)
WEBSITE: <http://www.ranbaxy.com>
CIN : L24231PB1961PLC003747

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA

PHONE: +91-124-4135000 FAX: +91-124-4106490

E-mail: secretarial@ranbaxy.com

The dosage regimen for Synriam™ is simple as the patient is required to take just one tablet per day, for three days, compared to other medicines where two to four tablets are required to be taken, twice daily, for three or more days. This makes Synriam™ a convenient option, leading to better compliance. The drug is also independent of dietary restrictions for fatty foods or milk, as is the case with older anti-malarial therapies. Since Synriam™ has a synthetic source, unlike artemisinin-based drugs, production can be scaled up whenever required and a consistent supply can be maintained at a low cost.

There was a critical need for a new anti-malaria drug that would address the existing challenges of resistance to available drugs, price fluctuations, supply constraints and high pill burden. Synriam™ address all these issues that are associated with the most commonly used therapies and is highly effective.

Synriam™, is a new age therapy recommended for the treatment of uncomplicated *Plasmodium falciparum* malaria, in adults. Synriam™ was launched by Ranbaxy on World Malaria Day, April 25, 2012 in India. Since its launch, the drug has successfully treated around one million patients in India.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com

Our Philosophy: Quality and Patients First.

For further information please contact:

Koji Ogawa

Head - Corporate Services

email: koji.ogawa@ranbaxy.com

Tel: +91-124-4135620



RANBAXY LABORATORIES LIMITED

HEAD OFFICE: 12TH FLOOR, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI - 110019

REGISTERED OFFICE: A-41, INDUSTRIAL AREA PHASE VIII-A, SAHIBZADA AJIT SINGH NAGAR, MOHALI - 160071 (PUNJAB)

WEBSITE: <http://www.ranbaxy.com>

CIN : L24231PB1961PLC003747

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA
PHONE: +91-124-4135000 FAX: +91-124-4106490
E-mail: secretarial@ranbaxy.com

Krishnan Ramalingam

General Manager – Global Corporate Communications

email: krishnan.ramalingam@ranbaxy.com

Mobile: 9810042540

Gaurav Chugh

Senior Manager – Global Corporate Communications

email: gaurav.chugh@ranbaxy.com

Mobile: 9810471414



RANBAXY LABORATORIES LIMITED

HEAD OFFICE: 12TH FLOOR, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI – 110019

REGISTERED OFFICE: A-41, INDUSTRIAL AREA PHASE VIII-A, SAHIBZADA AJIT SINGH NAGAR, MOHALI - 160071 (PUNJAB)

WEBSITE: <http://www.ranbaxy.com>

CIN : L24231PB1961PLC003747